M. Scot Roberts - Jan 30, 2024 Form 4 Insider Report for Altimmune, Inc. (ALT)

Role
Chief Scientific Officer
Signature
/s/ Richard I. Eisenstadt, as Attorney-in-Fact
Stock symbol
ALT
Transactions as of
Jan 30, 2024
Transactions value $
-$10,785
Form type
4
Date filed
2/1/2024, 06:03 PM
Previous filing
Jan 29, 2024
Next filing
Feb 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALT Common Stock, par value $0.0001 Options Exercise $0 +9.28K +45.41% $0.00 29.7K Jan 30, 2024 Direct F1
transaction ALT Common Stock, par value $0.0001 Tax liability -$26.5K -2.71K -9.12% $9.80 27K Jan 30, 2024 Direct F2
transaction ALT Common Stock, par value $0.0001 Award $15.8K +5.86K +21.71% $2.69 32.9K Jan 31, 2024 Direct F3, F4
holding ALT Common Stock, par value $0.0001 15 Jan 30, 2024 Shares held by spouse of Reporting Person

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALT Restricted Stock Units Options Exercise $0 -9.28K -25% $0.00 27.8K Jan 30, 2024 Common Stock, par value $0.0001 9.28K Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.
F2 Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs.
F3 These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2023 through January 31, 2024.
F4 In accordance with the ESPP, these shares were purchased based on 85% of the opening price of the issuer's common stock on August 1, 2023.
F5 The RSUs become vested in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.